Topical Corticosteroid Phobia Among Women Affected With Vulvar Lichen Sclerosus: Results From a Cross-sectional Survey.
Journal
Journal of lower genital tract disease
ISSN: 1526-0976
Titre abrégé: J Low Genit Tract Dis
Pays: United States
ID NLM: 9704963
Informations de publication
Date de publication:
12 Feb 2024
12 Feb 2024
Historique:
medline:
13
2
2024
pubmed:
13
2
2024
entrez:
12
2
2024
Statut:
aheadofprint
Résumé
Topical corticosteroid (TC) phobia (TCP) is common in subjects affected with chronic inflammatory skin diseases who need prolonged corticosteroid treatments. The aim of this study was to assess TCP in women affected with vulvar lichen sclerosus (VLS). This observational, cross-sectional study included adult patients with VLS who either started or were undergoing a TC treatment at our vulva unit between May 2022 and May 2023. All patients completed the self-administered TOPICOP questionnaire, which is validated for measuring concerns, worries, and beliefs about TC use. The scores obtained were analyzed in relation to demographic, history, and clinical data. The majority of the 165 (92.1%, 66.5 ± 11.9 years) included patients who had previously undergone TC treatments, mostly for VLS; 81.8% of them had received information about TCs, mainly from dermatologists (86.7%). The median global TOPICOP score was 16.7% (interquartile range. 8.3-30.6), corresponding to a raw median value of 6.0 (interquartile range, 3.0-11.0). The median subscores for the 2 TOPICOP domains, namely, mistaken beliefs and worries about TCs, were equal to each other. At multivariate analysis, none of the collected variables showed a significant association with the degree of TCP. In our VLS patients, TCP resulted rather low, probably because of the small skin area being treated and the high percentage of women who had already used TCs and who had received information about them from a dermatologist. This latter point suggests that adequate counseling could be a strong basis for greater awareness and serenity in the long-term use of TCs.
Identifiants
pubmed: 38346422
doi: 10.1097/LGT.0000000000000800
pii: 00128360-990000000-00102
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024, ASCCP.
Déclaration de conflit d'intérêts
The authors have declared they have no conflicts of interest.
Références
Tran DA, Tan X, Macri CJ, et al. Lichen sclerosus: an autoimmunopathogenic and genomic enigma with emerging genetic and immune targets. Int J Biol Sci 2019;15:1429–39.
Corazza M, Schettini N, Zedde P, et al. Vulvar lichen sclerosus from pathophysiology to therapeutic approaches: evidence and prospects. Biomedicine 2021;9:950.
Kirtschig G, Becker K, Günthert A, et al. Evidence-based (S3) guideline on (anogenital) lichen sclerosus. J Eur Acad Dermatol Venereol 2015;29:e1–43.
Chi CC, Kirtschig G, Baldo M, et al. Topical interventions for genital lichen sclerosus. Cochrane Database Syst Rev 2011;2011:CD008240.
Lewis FM, Tatnall FM, Velangi SS, et al. British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. Br J Dermatol 2018;178:839–53.
Borghi A, Corazza M. Novel therapeutic approaches and targets for treatment of vulvar lichen sclerosus. Curr Pharm Biotechnol 2021;22:99–114.
Lee A, Bradford J, Fischer G. Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women. JAMA Dermatol 2015;151:1061–7.
Chin S, Scurry J, Bradford J, et al. Association of topical corticosteroids with reduced vulvar squamous cell carcinoma recurrence in patients with vulvar lichen sclerosus. JAMA Dermatol 2020;156:813–4.
Virgili A, Minghetti S, Borghi A, et al. Proactive maintenance therapy with a topical corticosteroid for vulvar lichen sclerosus: preliminary results of a randomized study. Br J Dermatol 2023;168:1316–24.
Corazza M, Borghi A, Minghetti S, et al. Clobetasol propionate vs. mometasone furoate in 1-year proactive maintenance therapy of vulvar lichen sclerosus: results from a comparative trial. J Eur Acad Dermatol Venereol 2016;30:956–61.
Contento M, Cline A, Russo M. Steroid phobia: a review of prevalence, risk factors, and interventions. Am J Clin Dermatol 2021;22:837–51.
Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis: a systematic review. JAMA Dermatol 2017;153:1036–42.
Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol 2011;165:808–14.
Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142:931–6.
Smith SD, Hong E, Fearns S, et al. Corticosteroid phobia and other confounders in the treatment of childhood atopic dermatitis explored using parent focus groups. Australas J Dermatol 2010;51:168–74.
Gustavsen HE, Gjersvik P. Topical corticosteroid phobia among parents of children with atopic dermatitis in a semirural area of Norway. J Eur Acad Dermatol Venereol 2016;30:168.
Mueller SM, Itin P, Vogt DR, et al. Assessment of ‘corticophobia’ as an indicator of non-adherence to topical corticosteroids: a pilot study. J Dermatol Treat 2017;28:104–11.
Moret L, Anthoine E, Aubert-Wastiaux H, et al. TOPICOP©: a new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents. PLoS One 2013;8:e76493.
Sousa VD, Rojjanasrirat W. Translation, adaptation and validation of instruments or scales for use in cross-cultural health care research: a clear and user-friendly guideline. J Eval Clin Pract 2011;17:268–74.
Stalder JF, Aubert H, Anthoine E, et al. Topical corticosteroid phobia in atopic dermatitis: international feasibility study of the TOPICOP score. Allergy 2017;72:1713–9.
Choi E, Chandran NS, Tan C. Corticosteroid phobia: a questionnaire study using TOPICOP score. Singap Med J 2020;61:149–53.
Moawad S, Mahé E, Aubert-Wastiaux H, et al. Topical corticosteroid concerns among parents of children with psoriasis versus atopic dermatitis: a French multicenter cross-sectional study. Am J Clin Dermatol 2018;19:261–5.
Delpero E, Sriharan A, Selk A. Steroid phobia in patients with vulvar lichen sclerosus. J Low Genit Tract Dis 2023;27:286–90.
Dufresne H, Bataille P, Bellon N, et al. Risk factors for corticophobia in atopic dermatitis. J Eur Acad Dermatol Venereol 2020;34:e846–9.
Bos B, Antonescu I, Osinga H, et al. Corticosteroid phobia (corticophobia) in parents of young children with atopic dermatitis and their health care providers. Pediatr Dermatol 2019;36:100–4.
Gomes TF, Kieselova K, Guiote V, et al. A low level of health literacy is a predictor of corticophobia in atopic dermatitis. An Bras Dermatol 2022;97:704–9.
Smith SD, Farrugia LL, Harris V, et al. Evaluation of the influence of family and friends, and the Internet on patient perceptions of long-term topical corticosteroid use. J Dermatol Treat 2017;28:642–6.
Hrin ML, Bray JK, Fleischer AB, et al. Assessing the relationship between topical corticosteroid phobia and susceptibility to misinformation in patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2022;36:e115–8.
Choi E, Tan KW, Tang F, et al. Efficacy of targeted education in reducing topical steroid phobia: a randomized clinical trial. J Am Acad Dermatol 2020;83:1681–7.
Feldman SR, Huang WW. Steroid phobia isn't reduced by improving patients' knowledge of topical corticosteroids. J Am Acad Dermatol 2020;83:e403–4.